Medical management of metastatic bone disease.
To highlight recent advances in the medical management of metastatic bone disease. Progress has been made in quality of life assessment and pain measurement; in novel ways to use bisphosphonates, especially in the adjuvant setting for prevention of bone metastases and in combination with other pharmaceutical agents, where synergistic enhancement holds high potential; in targeted therapies using novel agents, especially with denosumab which is approaching registration; in the use of bone biomarkers to direct therapy and as surrogate endpoints; in development of radiopharmaceuticals for improved treatment of disseminated bone pain. Metastatic bone disease continues to present management challenges, but these challenges are being met with an increased armamentarium of available interventions.